In NPC, combination therapies targeting PIK3CA and its co-mutated partners might be an avenue for improved outcomes, as mutations in PIK3CA, particularly hotspot variants like H1047R, are often linked to therapy resistance and poor outcomes in other cancers [50]. The gene discussed is PIK3CA; the disease is cancer.